GE unable to deliver Ceretec due to inclement weather

GE Healthcare announced to customers that it will experience an impending shortage in its Ceretec (technetium Tc-99m exametazime) supply due to the flooding of its manufacturing site in Gloucester, England, which will be temporarily closed. As a result of extreme weather throughout western England, the company announced that Ceretec will be temporarily off the market once its current supply has been exhausted.

Ceretec is an imaging agent for two different indications. One is for visualization of cerebral blood flow in stroke patients. The other is for labeling of white blood cells to localize intra-abdominal infection and inflammatory bowel disease. 

GE moved some of its product lines to another manufacturing site in Oslo, but Ceretec cannot be manufactured elsewhere due to licensing production and regulatory restraints.

The company stated that it is committed to restoring the Gloucester site as soon as possible, and that it has deployed resources to assist in the process.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Trimed Popup
Trimed Popup